

1 **Sex-specific metabolic pathways associate with Alzheimer's Disease (AD)**
2 **endophenotypes in the European Medical Information Framework for AD**
3 **Multimodal Biomarker Discovery cohort**

4

5 Jin Xu^{1,2}, Rebecca Green^{2,3}, Min Kim^{4, +}, Jodie Lord², Amara Ebshiana¹, Sarah Westwood⁵,
6 Alison L Baird⁵, Alejo J Nevado-Holgado⁵, Liu Shi⁵, Abdul Hye², Stuart G. Snowden^{1,+,±},
7 Isabelle Bos^{6,7}, Stephanie J. B. Vos⁷, Rik Vandenberghe⁶, Charlotte E. Teunissen⁸, Mara Ten
8 Kate^{6,8}, Philip Scheltens⁶, Silvy Gabel^{9,10,11}, Karen Meersmans^{10,11}, Olivier Blin¹², Jill
9 Richardson¹³, Ellen Elisa De Roock^{14,15}, Sebastiaan Engelborghs^{15,16}, Kristel Slegers^{17,18}, Régis
10 Bordet¹⁹, Lorena Rami²⁰, Petronella Kettunen²¹, Magda Tsolaki²², Frans R.J. Verhey²³, Daniel
11 Alcolea²⁴, Alberto Lleó²⁴, Gwendoline Peyratout²⁵, Mikel Tainta²⁶, Peter Johannsen²⁷, Yvonne
12 Freund-Levi^{28,29}, Lutz Frölich³⁰, Valerija Dobricic³¹, Giovanni B. Frisoni^{32,33}, José Luis
13 Molinuevo^{34,35}, Anders Wallin²¹, Julius Popp^{36,37}, Pablo Martinez-Lage³⁸, Lars Bertram^{39,40}, Kaj
14 Blennow^{41,42}, Henrik Zetterberg^{41,43,44,45}, Johannes Streffer¹⁵, Pieter Jelle Visser^{46,47}, Simon
15 Lovestone^{5,48}, Petroula Proitsi², *, Cristina Legido-Quigley^{1,4}, *, and on behalf of EMIF
16 Consortium

17

18 (1)Institute of Pharmaceutical Science, King's College London, London, United Kingdom, (2)Institute
19 of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's
20 College London, London, United Kingdom, (3) NIHR Maudsley Biomedical Research Centre, South
21 London and Maudsley NHS Trust, London, United Kingdom, (4)Steno Diabetes Center, Gentofte,
22 Denmark, (5)Department of Psychiatry, University of Oxford, Oxford, United Kingdom, (6)Department
23 of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam,
24 Amsterdam, Netherlands, (7)Department of Psychiatry and Neuropsychology, School for Mental Health
25 and Neuroscience, Alzheimer Centrum Limburg, Maastricht University, Maastricht, Netherlands,
26 (8)Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam,
27 Netherlands, (9)Department of Clinical Chemistry, Neurochemistry Laboratory, Amsterdam
28 Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands,
29 (10)Department of Neurosciences, Laboratory for Cognitive Neurology, Leuven, Belgium,
30 (11)University Hospital Leuven, Leuven, Belgium, (12)Aix-Marseille University-CNRS, Marseille,
31 France, (13)Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, United Kingdom,
32 (14)Vrije Universiteit Brussel, Brussels, Belgium, (15)Reference Center for Biological Markers of
33 Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium, (16)
34 Department of Neurology and Center for Neurosciences (C4N), UZ Brussel and Vrije Universiteit
35 Brussel (VUB), Brussels, Belgium, (17)Institute Born-Bunge, University of Antwerp, Antwerp,
36 Belgium, (18) Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology,
37 VIB, Antwerp, Belgium, (19)Université de Lille, Lille, France, (20)Alzheimer's Disease and Other
38 Cognitive Disorders Unit, Hospital Clínic of Barcelona, IDIBAPS, Barcelona, Spain, (21) Institute of
39 Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

40 (22)AHEPA University Hospital, Thessaloniki, Greece, (23)Alzheimer Center Limburg, School for
41 Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands, (24) Sant Pau Memory
42 Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, (25)Lausanne
43 University Hospital, Lausanne, Switzerland, (26) Fundación CITA-Alzhéimer Fundazioa, San Sebastian,
44 Spain, (27) Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark, (28) Department
45 of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska
46 Institutet, Department of Psychiatry in Region Örebro County and School of Medical Sciences, Faculty
47 of Medicine and Health, Örebro University, Örebro, Sweden, (29) Department of Old Age Psychiatry,
48 Psychology & Neuroscience, King's College, London, UK, (30) Department of Geriatric Psychiatry,
49 Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim,
50 Germany, (31) Lübeck Interdisciplinary Platform for Genome Analytics, Institutes of Neurogenetics and
51 Cardiogenetics, University of Lübeck, Lübeck, Germany, (32) University of Geneva, Geneva,
52 Switzerland, (33) IRCCS Fatebenefratelli, Brescia, Italy, (34) Barcelona Beta Brain Research Center,
53 Unversitat Pompeu Fabra, Barcelona, Spain, (35) University of Lille, Lille, France, (36) Old Age
54 Psychiatry, Department of Psychiatry, University Hospital Lausanne, Lausanne, Switzerland, (37)
55 Department of Geriatric Psychiatry, University Hospital of Psychiatry Zürich, Zürich, Switzerland, (38)
56 Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian, Spain, (39)
57 University of Oslo, Oslo, Norway, (40) University of Lübeck, Lübeck, Germany, (41) Clinical
58 Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, (42) Department of
59 Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg,
60 Mölndal, Sweden, (43) Institute of Neuroscience and Physiology, Department of Psychiatry and
61 Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden, (44) UK
62 Dementia Research Institute at UCL, London, United Kingdom, (45) Department of Neurodegenerative
63 Disease, UCL Institute of Neurology, London, United Kingdom, (46) Department of Psychiatry and
64 Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht,
65 Netherlands, (47) Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit
66 Amsterdam, Amsterdam UMC, Amsterdam, Netherlands, (48) Janssen-Cilag UK Ltd, Oxford, United
67 Kingdom, ⁺Present address - Copenhagen Prospective Studies on Asthma in Childhood, Herlev and
68 Gentofte Hospital, University of Copenhagen, Denmark, ⁺⁺Present address –Department of Biological
69 Sciences, Royal Holloway, University of London, London, United Kingdom.

70

71 **Key words:** sex, Alzheimer's disease, metabolomics, metabolic pathway, blood,
72 vanillylmandelate, tryptophan betaine

73

74 **Conflicts of interest:** KB and HZ have served as consultants at scientific advisory
75 boards, or at data monitoring committees for Abcam, Axon, Biogen,
76 JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, NovartisEisai, Denali, Roche

77 Diagnostics, and Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics,
78 Nervgen, AZTherapies and CogRx, have given lectures in symposia sponsored by
79 Cellectricon, Fujirebio, Alzecure and Biogen, and are co-founders of Brain Biomarker
80 Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator
81 Program (outside the submitted work).
82 DA participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and
83 received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka
84 Farmacéutica S.L. and Esteve Pharmaceuticals S.A.
85 The other authors declare no conflict of interest.

86 **Abstract**

87 **BACKGROUND:** Physiological differences between males and females could
88 contribute to the development of AD. Here, we examined metabolic pathways that may
89 lead to precision medicine initiatives.

90

91 **METHODS:** We explored whether sex modifies the association of 540 plasma
92 metabolites with AD endophenotypes including diagnosis, CSF biomarkers, brain
93 imaging, and cognition using regression analyses for 695 participants (377 females),
94 followed by sex-specific pathway overrepresentation analyses, *APOE* ϵ 4 stratification
95 and assessment of metabolites' discriminatory performance in AD.

96

97 **RESULTS:** In females with AD, vanillylmandelate (tyrosine pathway) was increased
98 and tryptophan betaine (tryptophan pathway) was decreased. The inclusion of these two
99 metabolites (AUC = 0.83, SE = 0.029) to a baseline model (covariates + CSF
100 biomarkers, AUC = 0.92, SE = 0.019) resulted in a significantly higher AUC of 0.96
101 (SE = 0.012). Kynurenate was decreased in males with AD (AUC = 0.679, SE = 0.046).

102

103 **CONCLUSIONS:**

104 Metabolic sex-specific differences were reported, covering neurotransmission and
105 inflammation pathways with AD endophenotypes. Two metabolites, in pathways
106 related to dopamine and serotonin, associated to females, paving the way to
107 personalised treatment.

108

109 **1 Background**

110 Alzheimer's disease (AD) is the most common neurodegenerative dementia, making it
111 a major source of global morbidity and mortality. Current clinical diagnosis of AD
112 relies on a battery of cognitive tests combined with structural and functional imaging
113 and cerebrospinal fluid (CSF) biomarkers (1). Studies on mechanisms and biomarkers
114 of AD are attracting considerable interest due to the challenge of diagnosing cognitively
115 normal people during the preclinical phase of the disease.

116

117 Biomarkers of AD can be described in the ATN framework, grouped into those of β
118 amyloid ($A\beta$) deposition, pathological tau, and neurodegeneration (2). This ATN
119 descriptive classification system is independent to clinically defined diagnostic criteria
120 and eases the categorisation of multidomain biomarker findings at the individual level
121 (3). $A\beta$ (measured by CSF $A\beta_{42/40}$ or amyloid PET or CSF $A\beta_{42}$) and tau (evaluated by
122 CSF phosphorylated tau or tau PET) are being refined as the primary mediators of AD-
123 related synaptic loss and eventual neuronal death (4). AD neurodegeneration or
124 neuronal injury can be quantitatively or topographically estimated by CSF t-tau, [^{18}F]
125 fluorodeoxyglucose-positron emission tomography (FDG-PET), or structural MRI (5).
126 Although there are challenges of measuring biomarkers for brain diseases in the blood
127 (low concentrations and expression in non-cerebral tissues), blood-based biomarkers
128 are easily accessible, minimally invasive and scalable for large scale use. Recently,
129 success in detecting AD and predicting future disease progression has been achieved

130 particularly for the application of glial fibrillary acidic protein (GFAP), plasma
131 phospho-tau181 and phospho-tau217 (6–8).

132

133 Additionally to the above-mentioned biomarkers, AD risk factors include age, as well
134 as genetic, environmental and modifiable lifestyle factors (9). Sex-related differences
135 in brain structure and function have also been widely discussed (10,11), and if we know
136 more about whether sex-specific associations exist and the biological underpinnings of
137 these relationships, this may help guide more personalised treatments (12). Studies have
138 suggested that females are at greater risk for developing AD when compared to males.
139 The UK dementia report states that more females have AD and that this trend is likely
140 to remain with a F:M ratio of approximately 2 to 1 in the projected dementia incidence
141 for 2051 (13). Although it has been recently reported that selective survival may
142 contribute to sex/gender differences in dementia incidence, this does not preclude the
143 additional contributions from biological mechanisms (14).

144

145 Our previous studies using smaller cohorts have shown that i) plasma metabolites have
146 the potential to match the AUC of well-established AD CSF biomarkers through
147 machine learning approach (sample size N = 357) and ii) primary fatty amides were
148 associated with AD endophenotypes (sample size N = 593) (15,16). In the present
149 study, we performed metabolomics in 102 additional participants to a total of 695 and
150 aimed to explore whether sex modifies the association of plasma metabolites with AD

151 endophenotypes. Linear and logistic regressions were performed to investigate the
152 association of plasma metabolite levels with AD endophenotypes (CSF biomarkers,
153 brain MRI, cognition measures and diagnosis) in the full cohort including a sex
154 interaction term, followed by sex-stratified analyses and pathway analyses. Prediction
155 models based on logistic and linear regression were then built to assess AD biomarker
156 performance in each sex stratum. The study design is illustrated in Supplementary
157 Figure S1.

158 **2 Methods**

159 2.1 Participants

160 This study included 695 participants consisting of 377 females and 318 males from the
161 European Medical Information Framework for Alzheimer's Disease Multimodal
162 Biomarker Discovery (EMIF-AD MBD) (17). There were 283 control (CTL)
163 participants, 275 participants with mild cognitive impairment (MCI) and 137 AD
164 dementia patients. Participants were included from three multicenter studies: EDAR (n
165 = 84) (18), PharmaCog (n = 40) (19), DESCRIPA (n = 16) (20), and eight single center
166 studies: Amsterdam (n = 147) (21), Antwerp (n = 133) (22), IDIBAPS (n = 93) (23),
167 Leuven (n = 53) (24), San Sebastian GAP (n = 40) (25), Barcelona-Sant Pau (n = 35)
168 (26), Gothenburg (n = 34) (27), Lausanne (n = 20) (28).

169

170 2.2 Clinical and cognitive data

171 Neuropsychological tests measuring five different cognitive domains were available.
172 Briefly, these were memory (delayed and immediate), language, attention, executive
173 function, and visuo-construction (Table 1). Hippocampal volume (left, right and sum,
174 adjusted for intracranial volume ICV) and cortical thickness (average across the whole
175 brain and in AD signature regions) were also available (Table 1). The definition of CTL
176 was a normal performance on neuropsychological assessment (within 1.5 SD of the
177 average for age, gender and education). MCI was defined as having cognitive
178 complaints and performance below 1.5 SD of the average on at least one

179 neuropsychological test but no dementia (29). AD-type dementia diagnosis was made
180 based on a clinical diagnosis, using the National Institute of Neurological and
181 Communicative Disorders and Stroke – Alzheimer’s Disease and Related Disorders
182 Association criteria (30). Details on the neuropsychological test, amyloid (CSF A $\beta_{42/40}$
183 ratio of the central analyses or the local CSF A β_{42} value or the standardized uptake
184 value ratio (SUVR) on an amyloid-PET scan) and tau level measurements, magnetic
185 resonance imaging (MRI) and genetic analyses can be found in Bos *et al.* (17).

186

187 2.3 Metabolomics data

188 Relative levels of 665 plasma metabolites were measured in fasted blood samples by
189 *Metabolon, Inc.* Metabolomics experiments were performed with an additional 102
190 participants, and details of the analytical method for all (N=695) can be found in Kim
191 *et al.* (16). After removing metabolites with more than 20% missing values, 540
192 metabolites with known identity were included for further analyses. Log10
193 transformation and scaling (mean of zero and standard deviation of one) were applied
194 to metabolomics data after missing values were imputed with the k-nearest neighbour
195 algorithm (k=10, “impute” package for R). Single outlying values beyond three
196 standard deviations were further removed.

197

198 2.4 Statistical analyses

199 Prior to statistical analyses, baseline characteristics were compared among the three
200 diagnostic groups using the ANOVA for continuous variables and Chi-square test for
201 categorical variables (Table 1). The 15 AD endophenotypes were classified into four
202 collections: CSF biomarkers (three continuous variables; A β , p-tau, t-tau), brain MRI
203 measurements (five continuous variables; hippocampal left, right and sum volume,
204 average cortical thickness in whole brain and AD regions), cognition measures (six
205 continuous variables; attention, executive, language, memory delay, memory
206 immediate, visuoconstruction) and diagnosis (one binary variable; AD versus CTL,
207 MCI excluded).

208

209 Regression analyses evaluated the association between metabolites (predictors) and AD
210 endophenotypes (outcomes). Linear regression was used for continuous AD variables
211 and logistic regression was used for diagnosis. An interaction term between sex and
212 metabolites was included in each model to test whether sex modified the association of
213 metabolites with AD endophenotypes. All models were further sex-stratified when
214 there was evidence of significant sex-metabolite interaction ($P < 0.05$). Each regression
215 model was adjusted for age at sampling, years of education, batch and presence of the
216 *APOE* $\epsilon 4$ allele ($\epsilon 4$ carrier versus no $\epsilon 4$ carrier). The analyses of *APOE* $\epsilon 4$ (+/-) -by-
217 metabolite interaction effects were also conducted using the same approach described
218 above where sex was included as a covariate instead (Supplementary methods and

219 results). To account for the number of tests performed and the correlations between
220 metabolites, a Bonferroni-adjusted significance threshold ($P < 8.17e-04$) was set as 0.05
221 divided by the number of independent metabolites ($n = 61$) from 230 metabolites used
222 in sex-stratified analyses (“independent tests” package in Python
223 https://github.com/hagax8/independent_tests). Exploratory pathway enrichment
224 analyses were additionally performed (Supplementary methods and results).

225

226 Individual metabolites showing association with diagnosis ($P < 8.17e-04$) were
227 investigated as sex-specific biomarkers using prediction models (bootstrapped,
228 $n=1000$, “fbroc” package in R). To evaluate the prediction performance gained by
229 adding sex-specific biomarkers to baseline AD predictors, likelihood ratio test (“lmtest”
230 package in R) was employed followed by net reclassification index (NRI) analysis
231 (“nricens” package in R). The baseline model was built including both CSF biomarkers
232 and covariates. Sex-specific markers were then added, and their performance was
233 evaluated. The prevalence of AD in the dataset (excluding MCI) was utilised as the
234 event rate and participants were categorised into two groups: below and above the event
235 rate. The NRI categorized at the event rate, denoted $NRI(p)$, is a robust measure to
236 model miscalibration (31). We calculated both event NRI and non-event NRI and took
237 the sum as the final $NRI(p)$ (32). It has been reported that adding a variable/variables
238 that has/have a moderate or large effect size (Cohen’s D equal to 0.5 or 0.8,
239 respectively) can yield $NRI(p)$ values between 0.018 and 0.197, depending on the

240 discrimination of the initial model (AUC) (33). To provide insight into the links
241 between diagnosis and other AD endophenotypes, metabolites that were nominally
242 associated with diagnosis and at least one other AD variable were studied further. All
243 statistical analyses were performed using R Studio (version 1.3.1056) unless otherwise
244 stated.

245 **3 Results**

246 3.1 Demographics

247 The characteristics of the study participants are presented in Table 1. There were no
248 differences in sex distribution among the three diagnostic groups. AD and MCI
249 participants were older compared to CTL participants. There were more *APOE ε4*
250 carriers in the AD group compared to the other two groups ($P < 0.01$). AD participants
251 had lower CSF A β , p-tau, and t-tau z-score levels ($P < 0.01$) compared to the other two
252 groups, which means lower CSF A β_{42} and CSF A $\beta_{42/40}$ ratio. AD participants also had
253 smaller hippocampal volumes (left, right, and sum) and on average smaller cortical
254 thickness in AD signature regions (all, $P < 0.01$). No significant differences were
255 observed for average cortical thickness across the whole brain between the three
256 diagnostic groups ($P \geq 0.05$).

257

258 3.2 Sex-specific association of blood metabolites with AD endophenotypes

259 To identify whether sex modified the association between blood metabolites and the
260 AD endophenotypes included in this study, we built multivariable linear and logistic
261 regression models between each of the 540 metabolite and each of the 15 AD
262 endophenotypes from four collections (CSF biomarkers, brain MRI measurements,
263 cognition measures and diagnosis) by including an interaction term between sex and
264 each metabolite. We found that sex modified the association of 230 metabolites with
265 AD endophenotypes (Supplementary Table S1). Of these, 38 metabolites showed sex-

266 interactions with CSF biomarkers, 152 with cognition measurements, 79 with brain
267 MRI variables, and 30 with diagnosis (AD/CTL).

268

269 Metabolites that showed an interaction with sex at $P < 0.05$ were further investigated for
270 associations with AD endophenotypes in sex-stratified regression analyses.

271 Specifically, only metabolites that showed an interaction with sex in the full dataset,

272 and that associated with the same endophenotype in our sex-stratified analyses, were

273 listed. Stratifying participants by sex revealed that two metabolites, vanillylmandelate

274 (VMA) and tryptophan betaine (Figure 2A & 2B), were associated with AD in females

275 after Bonferroni correction ($P < 8.17e-04$) ($\beta = 0.77$, 95% CI = 0.40 to 1.18, $P = 1.14e-$

276 04 and $\beta = -0.73$, 95% CI = -1.12 to -0.36, $P = 1.48e-04$, respectively), and 116 of 230

277 metabolites at the nominal significance level. In parallel, one metabolite, kynurenate,

278 was associated with AD in males after Bonferroni correction ($P < 8.17e-04$) ($\beta = -1.04$,

279 95% CI = -1.58 to -0.54, $P = 7.63e-05$) (Table 2) and 100 of 230 metabolites showed

280 nominally significant associations in males (Supplementary Table S1).

281

282 In addition to the single metabolite analysis, pathway-based exploratory analysis was

283 performed to provide more insights into these metabolites in AD at a systems level

284 (Supplementary methods and results). We also investigated metabolites that showed

285 sex-specific associations with diagnosis and at least one other AD phenotype ($P < 0.05$).

286 As shown in Figure 1, five metabolites showed associations only in females. These

287 included isovalerylcarnitine from ‘leucine, isoleucine and valine metabolism’ sub-
288 pathway, carotene diol (1) and carotene diol (2) from ‘vitamin A metabolism’ sub-
289 pathway, as well as phosphatidylcholine (p16:0/16:1), 1-linoleoyl glycerol and methyl
290 4-hydroxybenzoate sulfate. The above mentioned two sub-pathways were enriched for
291 two collections of endophenotypes, cognition and diagnosis, respectively
292 (Supplementary Table S4). Moreover, six metabolites showed associations in males:
293 lysophosphocholine (18:2) (LPC 18:2), sphingomyelin (d38:0), 5-(galactosylhydroxy)-
294 L-Lysine, kynurenate, N-acetylneuraminic acid and xanthurenate (Supplementary Figure
295 S2-S12).

296

297 3.3 Interactive effect of *APOE* $\epsilon 4$ and sex

298 After investigating how sex exert metabolite associations with AD endophenotypes, we
299 also performed association analyses for all 540 metabolites with 15 AD
300 endophenotypes from four categories, now stratified by *APOE* $\epsilon 4$ status and adjusted
301 for sex (Supplementary methods and results). Supplementary Table S2 summarises the
302 numbers of number of metabolites showed association with each of the AD
303 endophenotypes in the whole cohort and each *APOE* $\epsilon 4$ +/- stratum. To investigate
304 potential relationships between sex and *APOE* $\epsilon 4$ status on the metabolomic level, we
305 compared the metabolites identified in either sex group and *APOE* $\epsilon 4$ carrier
306 stratification analyses (Supplementary Table S1 and Table S2). There is no overlap of
307 metabolite that associated with the same AD endophenotype between female/male and

308 *APOE* $\epsilon 4$ + stratum observed at Bonferroni significance thresholds (Supplementary
309 methods and results).

310

311 3.4 Sex-specific metabolites as diagnostic biomarkers

312 We further explored sex-specific metabolites, VMA, tryptophan betaine, and
313 kynurenate, as diagnostic biomarkers, that were significant following Bonferroni
314 correction in sex stratified regression analyses. In addition, we tested if these three
315 metabolites were associated to drugs (n = 2, hydroquinone sulfate and salicylate, sample
316 size n = 695), and AD medications (n = 2, acetyl -cholinesterase inhibitors or other AD
317 drugs, sample size = 225). Regression models showed no associations between the three
318 metabolites and drugs at $P < 8.17e-04$ (data not shown).

319

320 In females, a receiver operating characteristic (ROC) curve (bootstrapped) for VMA
321 and tryptophan betaine was built and is presented in Figure 2C (AUC = 0.83 for AD
322 versus controls, SE = 0.029, 95% CI = 0.777 to 0.889). We then examined how well
323 other AD endophenotypes would discriminate AD cases from controls. CSF biomarkers
324 ($A\beta$, t-tau and p-tau) produced an AUC of 0.89 (SE = 0.025, 95% CI = 0.836 to 0.93),
325 covariates (age at sampling, education years, sampling batch and *APOE* $\epsilon 4$ status)
326 produced an AUC of 0.83 (SE = 0.031, 95% CI = 0.763 to 0.886), CSF biomarkers and
327 covariates together produced AUC of 0.92 (SE = 0.019, 95% CI = 0.881 to 0.954). The
328 combination of the two female-specific biomarkers, CSF biomarkers and covariates

329 produced AUC of 0.96 (SE = 0.012, 95% CI = 0.93 to 0.978). Bootstrapping results of
330 standard error and 95% confident interval for AUCs from the ROC curves are listed in
331 Supplementary Table S5.

332

333 In the male cohort we then built a regression model followed by a ROC curve for
334 kynurenate (Figure 2D). The resulting AUC was 0.68 (SE = 0.046, 95% CI = 0.593 to
335 0.765). This value was again compared to the CSF biomarkers (AUC = 0.91, SE =
336 0.026, 95% CI = 0.852 to 0.954), covariates (AUC = 0.77, SE = 0.042, 95% CI = 0.68
337 to 0.848), both CSF biomarkers & covariates (AUC = 0.932, SE = 0.019, 95% CI =
338 0.89 to 0.965), and the combination of kynurenate, CSF biomarkers and covariates
339 (AUC = 0.93, SE = 0.02, 95% CI = 0.888 to 0.966). Furthermore, the AUC of CSF
340 biomarkers, covariates, VMA and tryptophan betaine, kynurenate, and combinations of
341 them were explored in the full dataset (males and females combined) (Figure 2E). An
342 increase of AUC from 0.92 to 0.94 was observed when VMA and tryptophan betaine
343 were added to the panel of CSF biomarkers and covariates, while the addition of
344 kynurenate resulted in the same AUC of 0.92 in the full cohort.

345 Finally, the application of NRI to regression models revealed that, when examining the
346 effect of VMA and tryptophan betaine together in the female sub-dataset, the event
347 NRI, non-event NRI and NRI(p) were 0.04, 0.039, and 0.079 (all above the critical
348 value 0), respectively (Supplementary Figure S13A). However, adding kynurenate to
349 the model in the male sub-dataset yielded nil event NRI, non-event NRI and NRI(p)

350 values (Supplementary Figure S13B). When investigating these sex-specific
351 biomarkers in the full dataset, an NRI(p) of 0.0516 was observed for the two female-
352 specific markers, albeit an NRI(p) of -0.0079 was seen for the male-specific marker
353 (Supplementary Figure S13C & S13D).

354 **4 Discussion**

355 In this study, we measured 665 plasma metabolites in 695 participants: 377 females and
356 318 males. We used a combination of linear and logistic regression analyses as well as
357 pathway enrichment analyses to investigate sex-specific associations between
358 metabolites and AD endophenotypes. For a follow-up investigation, we found that none
359 of the nine metabolites (four primary fatty acid amides, three amino acids, and two
360 lipokines) demonstrating association with AD in our previous study (16) showed
361 interaction with sex in this study which included an additional 102 participants. Overall,
362 we identified ten sub-pathways that showed sex-specific associations in our exploratory
363 pathway analysis (Supplementary methods and results). A number of metabolites
364 demonstrated associations with clinical AD diagnosis and at least one additional AD
365 clinical biomarker. Finally, we report two metabolites, VMA and tryptophan betaine,
366 which had added value to discriminate in females AD cases from controls and
367 demonstrated improved prediction over traditional CSF biomarkers and covariates
368 (AUC of metabolites = 0.834, AUC of CSF markers = 0.884, AUC of CSF markers &
369 covariates = 0.92, total AUC = 0.955).

370

371 4.1 Metabolites associated with AD and other endophenotypes

372 When we investigated metabolites associated with diagnosis and at least one other AD
373 endophenotype, five out of 11 metabolites showed significant associations in females,
374 namely isovalerylcarnitine, methyl-4-hydroxybenzoate sulfate, carotene diol (1),

375 carotene diol (2), and 1-linoleoyl glycerol (Figure 1). Among these, isovalerylcarnitine,
376 a short chain acylcarnitine, showed positive associations with cortical thickness in AD
377 regions in females. Moreover, its concentration showed a gradual decrease from
378 cognitively normal group to MCI, and then AD patients. Whilst previous studies have
379 emphasised metabolite links to both sexes, our findings in females are consistent with
380 studies in which sex was not stratified. In these studies, decreased levels of
381 acylcarnitines in schizophrenia and AD were reported (34)(35), although the opposite
382 direction, higher levels of acylcarnitines in subjects with AD have also been observed
383 (36). Carotene diols are unoxxygenated carotenoids involved in vitamin A metabolism
384 and we observed decreased levels in AD patients, while other studies have also shown
385 that beta-carotene might protect against dementia (37).

386

387 Six metabolites associated with AD and at least one other AD endophenotype in males,
388 namely xanthurenate, N-acetylneuraminic acid, LPC (18:2), kynurenate, 5-
389 (galactosylhydroxy)-L-lysine, and SM(d38:0). While our study focuses on novel
390 metabolites with association to male sex, links to cognition and AD have been
391 previously reported. Xanthurenate and kynurenate are formed in the kynurenine
392 pathway by tryptophan degradation. They may play a physiological role in attentional
393 and cognitive processes, as well as act as a potential trait marker for schizophrenia (38).
394 The importance of lipid dynamics has been studied as an area of investigation in AD
395 (39). In this regard, we observed significantly increased levels of LPC (18:2) - a

396 glycerophospholipid - in males, although decreased plasma LPC (18:2) levels have
397 been reported in a non-targeted AD study (40).

398 4.2 Sex-specific biomarkers

399 In this study, we found three metabolites, VMA, tryptophan betaine and kynurenine in
400 the tyrosine and tryptophan pathways, to be associated with AD in two sex strata.
401 Kaddurah-Daouk *et al.* found that the level of VMA was elevated in AD versus controls
402 in CSF (41), in accordance with our findings. VMA is an end product of catecholamine
403 metabolism in the tyrosine-dopamine pathway (Supplementary Figure S14A)
404 metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO)
405 (41). Therefore, the observed increase in positive association with VMA could be the
406 result of the upregulation COMT and/or MAO in female AD patients. Indeed, oestrogen
407 turnover via COMT has been implicated in AD pathogenesis in ApoE-dependent
408 manner (42). In addition, the activation of MAO-B, the alternative pathway to VMA
409 metabolism, has been demonstrated in brains with AD (43).

410

411 Tryptophan betaine was the second female-specific AD marker in this study. An
412 important finding of this study is that metabolites that can act via the gut-brain axis
413 showed sex-specific associations. Tryptophan betaine is found in high fibre plants, and
414 it is also linked to microbiota in fibre-enriched diets (44). Koistinen *et al.* found that
415 tryptophan betaine correlated negatively with several bacterial taxa which have earlier
416 been associated with adverse effects in the gut and overall health in an in vitro model

417 of the human gastrointestinal system (44). It is an indole alkaloid composed of
418 tryptophan and three methyls (Supplementary Figure S14B) and has been found to have
419 neurological and glucose-lowering effects in rodents (45). Interestingly, it has been also
420 been reported as sleep-inducing and anti-inflammatory compound when tested in
421 animal models (45,46). Furthermore, in females, our pathway analyses revealed
422 enrichment in the tryptophan pathway for AD diagnosis (Supplementary methods and
423 results).

424 Another metabolite in the same pathway and that was decreased in male AD patients
425 specifically was kynurenate. It is produced via a secondary branch of the kynurenine
426 pathway through tryptophan degradation (Supplementary Figure S14B). This is in
427 agreement with studies with no sex-specific analyses, where kynurenine concentrations
428 were decreased in AD plasma/serum (36)(47). In the past it has been reported as an
429 endogenous excitatory amino acid receptor antagonist, as well as a neuroprotective
430 compound (48). Tryptophan is the parent metabolite in both the serotonin and
431 kynurenine pathways. Kynurenate can lead to attenuated glutamate neurotransmission
432 by antagonism of glutamate receptors and release, which consequently decreases
433 glutamate-evoked dopamine release in the striatum (49).

434

435 Both pathways, tyrosine-dopamine and tryptophan, have been reported to be linked to
436 inflammation in psychiatric disease (50). The predictive abilities of the two female- and
437 one male-specific biomarkers were initially evaluated by calculating the AUC, and

438 further assessed by NRI when compared to existing baseline models. NRI(p) of 0.079
439 and 0.052 were observed for the two female-specific markers in the female dataset and
440 the full dataset (Supplementary Figure S13A & S13C), respectively. With the baseline
441 AUC over 0.9, it has been reported that the effect size (Cohen's D) of adding the female-
442 specific markers could reach 0.8 (33). The increased AUC values, together with positive
443 NRI, support the hypothesis that female-specific AD markers add value to precision
444 medicine (31).

445

446 4.3 Limitations and conclusions

447 A limitation of this study is that, although it is relatively large, the number of
448 participants is still small particularly after sex-stratification. Also, results of this study
449 should be validated in an independent cohort. However, to avoid potential overfitting
450 all AUCs from ROC curves were bootstrapped 1000 times with 95% CIs and standard
451 errors presented. In addition, an important finding of this study is the gut-brain axis link
452 shown by the tryptophan betaine and VMA pathways in females, however no causal
453 implications can be drawn from our study. Additional limitations include survival and
454 selection bias inherent to observational studies. In summary, our study reports sex-
455 specific metabolic differences in AD and highlights two metabolites, both involved in
456 neurotransmission pathways as potential female-specific biomarkers in AD. This is the
457 first report that highlights female-specific and modifiable metabolites associated with
458 AD, paving the way to personalised treatment.

459 **Acknowledgements**

460 The authors thank the participants and families who took part in this research. The
461 authors would also like to thank all people involved in data and sample collection and/or
462 logistics across the different centres.

463

464 Funding: The present study was conducted as part of the EMIF-AD project, which has
465 received support from the Innovative Medicines Initiative Joint Undertaking under
466 EMIF grant agreement no. 115372, EPAD grant no. 115736, and from the European
467 Union's Horizon 2020 research and innovation programme under grant agreement No.
468 666992. Resources of which are composed of financial contribution from the European
469 Union's Seventh Framework Program (FP7/2007-2013) and EFPIA companies' in-kind
470 contribution. The DESCRIPA study was funded by the European Commission within
471 the fifth framework program (QLRT-2001-2455). The EDAR study was funded by the
472 European Commission within the fifth framework program (contract no. 37670). The
473 San Sebastian GAP study is partially funded by the Department of Health of the Basque
474 Government (allocation 17.0.1.08.12.0000.2.454.01.41142.001.H). The Leuven cohort
475 was funded by the Stichting voor Alzheimer Onderzoek (grant numbers #11020,
476 #13007 and #15005). The SPIN cohort (Barcelona) has received funding from
477 CIBERNED; Instituto de Salud Carlos III; jointly funded by Fondo Europeo de
478 Desarrollo Regional (FEDER), Unión Europea, "Una manera de hacer Europa";
479 Generalitat de Catalunya; Fundació "La Marató TV3" Fundació Bancària Obra Social

480 La Caixa; Fundación BBVA; Fundación Española para el Fomento de la Investigación
481 de la Esclerosis Lateral Amiotrófica (FUNDELA); Global Brain Health Institute;
482 Fundació Catalana Síndrome de Down; and Fundació Víctor Grífols i Lucas. KB and
483 HZ are Wallenberg Scholars supported by grants from the Swedish Research Council
484 (#2017-009152018-02532), the European Research Council (#681712), Swedish State
485 Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery
486 Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish
487 Alzheimer2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-
488 21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon
489 Foundation (#AF-742881), the Erling-Persson Family Foundation, Stiftelsen för Gamla
490 Tjänarinnor, Hjärnfonden, Sweden (#FO2017-0243), the Swedish stateFO2019-0228),
491 the European Union's Horizon 2020 research and innovation programme under the
492 Marie Skłodowska-Curie grant agreement between the Swedish government and the
493 County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint
494 Program for Neurodegenerative Disorders (JPND2019-466-236No 860197
495 (MIRIADE), and the National UK Dementia Research Institute at UCL. Research at
496 VIB-Antwerp was in part supported by the University of Health (NIH), USA (grant
497 #1R01AG068398-01) Antwerp Research Fund. PK is supported by the Swedish state
498 under the agreement between the Swedish government and the County Councils, the
499 ALF-agreement ALFGBG-724331 and AW by ALFGBG-720661. DJM was partially
500 supported by a grant from the National Institutes of Health (R15-GM107864). YFL is

501 supported by The Brain Foundation (Hjärnfonden FO2018-0315), Stohne's Foundation
502 (Stohnes Stiftelse), Gamla Tjänarinnor Stftelse, Stohnes Stiftelse, Särfond 31S
503 Research Fund Region Örebro län Sweden, Familjen Kamprad Stiftelse (ref 20210034,
504 AFA 200386). DA received support from Institute of Health Carlos III (ISCIII),
505 Spain PI18/00435 and INT19/00016, and by the Department of Health
506 Generalitat de Catalunya PERIS program SLT006/17/125. JL is funded by the van
507 Geest endowment fund. RG is funded by the National Institute for Health Research
508 (NIHR) Biomedical Research Centre. JX and CLQ thank Lundbeck Fonden for the
509 support.

510 Tables

511 **Table 1.** Sample demographics.

	Sample size	CTL	MCI	AD	P- value*
Age	695	65 (7.9)	70 (8.1)	70 (8.49)	6.52e-14
Sex (f/m)	377/318	155/128	141/134	81/56	3.13e-01
<i>APOE</i> $\epsilon 4$ (+/-)	348/347	111/172	153/122	84/53	7.30e-06
A β z-score	693	-0.22 (1.11)	-0.82 (0.99)	-1.22 (0.64)	<2.00e-16
p-tau z-score	640	-0.00087 (0.99)	-0.94 (1.38)	-1.31 (1.66)	<2.00e-16
t-tau z-score	637	0.032 (0.84)	-0.98 (1.25)	-1.65 (1.60)	<2.00e-16
Attention z-score	644	0.21 (1.13)	-0.91 (1.63)	-1.92 (1.99)	<2.00e-16
Executive z-score	526	0.16 (1.16)	-0.79 (2.04)	-2.26 (2.55)	<2.00e-16
Language z-score	674	-0.18 (0.99)	-1.0 (1.25)	-2.08 (1.27)	<2.00e-16
Memory delayed z-score	551	-0.037 (1.15)	-1.52 (1.40)	-2.40 (1.070)	<2.00e-16
Memory immediate z-score	637	-0.50 (1.77)	-1.57 (1.39)	-2.34 (1.24)	<2.00e-16
Visuo-construction z-score	436	-0.20 (1.34)	-0.14 (1.47)	-1.36 (1.98)	1.93e-08
Hippocampal left	455	3761.21 (453.57)	3272.52 (634.570)	3017.90 (487.63)	<2.00e-16
Hippocampal right	455	3878.12 (436.76)	3388.14 (628.15)	3146.17 (500.52)	<2.00e-16
Hippocampal sum	455	7639.32 (857.95)	6660.69 (1210.53)	6182.10 (913.81)	<2.00e-16
Cortical thickness in whole brain	420	2.30 (0.12)	2.30 (0.11)	2.28 (0.11)	5.47e-01
Cortical thickness in AD regions	420	2.66 (0.16)	2.63 (0.15)	2.58 (0.17)	1.95e-04
Taking AChEI, yes/no	76/149	1/40	50/78	25/31	1.3e-05
Taking other AD medications, yes/no	23/201	0/41	16/112	7/48	1.55e-01

512 Results are mean (standard deviation) for continuous variables.

513 A β , amyloid beta; AChEI, acetylcholine esterase inhibitor; AD, Alzheimer's disease; *APOE* $\epsilon 4$, apolipoproteinE $\epsilon 4$;
514 MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; CTL, control; ROD, rate of cognitive
515 decline.


516 *Differences in the means/frequencies of clinical/demographic variables were tested using ANOVA or χ^2 test.

517 **Table 2.** Association results for metabolites in relation to diagnosis (AD/CTL) in the
 518 full cohort and after stratification by sex.
 519

<i>Metabolite</i>	<i>Interaction effect</i>	<i>Interaction P-value</i>	<i>Female effect</i>	<i>Female P-value</i>	<i>95% CI</i>	<i>Male effect</i>	<i>Male P-value</i>	<i>95% CI</i>
VMA	0.84	1.66e-03	0.77	1.14e-04	0.04 to 1.18	-0.16	0.438	
Tryptophan betaine	-0.58	1.92e-02	-0.73	1.48e-04	-1.12 to 0.36	-0.015	0.934	
Kynurenate	0.69	2.35e-02	0.37	0.043		-1.04	7.63e-05	-1.58 to 0.54

520 AD, Alzheimer's disease; CTL, controls, VMA, vanillylmandelate.


521 **Figures**



522

523

524 **Figure 1. Eleven metabolites showed associations with AD and one other**
525 **endophenotype.** Five plasma metabolites (with brown grid), isovalerylcarnitine,
526 methyl 4-, carotene diol (2), 1-linoleoyl glycerol and carotene diol (1), were
527 significantly associated with diagnosis and the other AD endophenotypes in female
528 group only. Six other metabolites (with blue grid), xanturenate, N-acetylneuraminic acid,
529 LPC (18:2), kynurenate, 5-(galactosylhydroxy)-L-lysine and SM (d38:0), showed
530 associations with diagnosis and AD variables in male group only.



531

532 **Figure 2. Box plots of two female biomarkers A) vanillylmandelate and B)**
 533 **tryptophan betaine, the p value (below Bonferroni significance threshold) and the**
 534 **association coefficient (beta) for metabolites in relation to diagnosis (AD/CTL) are**
 535 **shown above the box plots; ROC graphs, comparing area under curve (AUC) in**
 536 **predictive models using sex-specific biomarkers, CSF biomarkers, covariates, and**
 537 **the combination of them in C) the female sub-dataset; D) the male sub-dataset; E) the**
 538 **full cohort; F) Bar plot summarises the AUC of the above mentioned ROC curves**
 539 **together with standard errors after bootstrapping.**

540 **References**

- 541 1. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE,
542 et al. Alzheimer's disease. *The Lancet* [Internet]. 2021 Mar 2 [cited 2021 Mar 3];
543 Available from:
544 <https://www.sciencedirect.com/science/article/pii/S0140673620322054>
- 545 2. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al.
546 NIA-AA Research Framework: Toward a biological definition of Alzheimer's
547 disease. *Alzheimers Dement J Alzheimers Assoc.* 2018;14(4):535–62.
- 548 3. Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al.
549 A/T/N: An unbiased descriptive classification scheme for Alzheimer disease
550 biomarkers. *Neurology.* 2016 Aug 2;87(5):539–47.
- 551 4. Vinters HV. Emerging Concepts in Alzheimer's Disease. *Annu Rev Pathol Mech*
552 *Dis.* 2015 Jan 24;10(1):291–319.
- 553 5. Pike CJ. Sex and the development of Alzheimer's disease. *J Neurosci Res.* 2017
554 Jan 2;95(1–2):671–80.
- 555 6. Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et
556 al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a
557 diagnostic performance and prediction modelling study using data from four
558 prospective cohorts. *Lancet Neurol.* 2020;19(5):422–33.
- 559 7. Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al.
560 Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs
561 Other Neurodegenerative Disorders. *JAMA.* 2020 Aug 25;324(8):772–81.
- 562 8. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis
563 and monitoring in cognitively normal older people: a prospective memory clinic-
564 based cohort study - *The Lancet Healthy Longevity* [Internet]. [cited 2021 Mar
565 15]. Available from: [https://www.thelancet.com/journals/lanhl/article/PIIS2666-
566 7568\(20\)30061-1/fulltext](https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(20)30061-1/fulltext)
- 567 9. Xu W, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, et al. Meta-analysis of
568 modifiable risk factors for Alzheimer's disease. *J Neurol Neurosurg Psychiatry.*
569 2015 Dec;86(12):1299–306.
- 570 10. Ruigrok ANV, Salimi-Khorshidi G, Lai M-C, Baron-Cohen S, Lombardo MV,
571 Tait RJ, et al. A meta-analysis of sex differences in human brain structure.
572 *Neurosci Biobehav Rev.* 2014 Feb;39:34–50.

- 573 11. Mielke MM. Sex and Gender Differences in Alzheimer’s Disease Dementia.
574 Psychiatr Times. 2018 Nov;35(11):14–7.
- 575 12. Ferretti MT, Iulita MF, Cavedo E, Chiesa PA, Schumacher Dimech A,
576 Santucciono Chadha A, et al. Sex differences in Alzheimer disease — the gateway
577 to precision medicine. *Nat Rev Neurol*. 2018 Aug 1;14(8):457–69.
- 578 13. Dementia UK: Update [Internet]. [cited 2020 Aug 28]. Available from:
579 https://www.alzheimers.org.uk/sites/default/files/migrate/downloads/dementia_u
580 [k_update.pdf](https://www.alzheimers.org.uk/sites/default/files/migrate/downloads/dementia_u)
- 581 14. Evaluation of Selective Survival and Sex/Gender Differences in Dementia
582 Incidence Using a Simulation Model | Dementia and Cognitive Impairment |
583 JAMA Network Open | JAMA Network [Internet]. [cited 2021 Mar 22]. Available
584 from:
585 [https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777217?utm_so](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777217?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=031121#.YEob6Li2E7w.twitter)
586 [urce=twitter&utm_campaign=content-](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777217?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=031121#.YEob6Li2E7w.twitter)
587 [shareicons&utm_content=article_engagement&utm_medium=social&utm_term](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777217?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=031121#.YEob6Li2E7w.twitter)
588 [=031121#.YEob6Li2E7w.twitter](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777217?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=031121#.YEob6Li2E7w.twitter)
- 589 15. Stamate D, Kim M, Proitsi P, Westwood S, Baird A, Nevado-Holgado A, et al. A
590 metabolite-based machine learning approach to diagnose Alzheimer-type
591 dementia in blood: Results from the European Medical Information Framework
592 for Alzheimer disease biomarker discovery cohort. *Alzheimers Dement Transl*
593 *Res Clin Interv*. 2019 Dec 18;5:933–8.
- 594 16. Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, et al. Primary
595 fatty amides in plasma associated with brain amyloid burden, hippocampal
596 volume, and memory in the European Medical Information Framework for
597 Alzheimer’s Disease biomarker discovery cohort. *Alzheimers Dement*. 2019 Jun
598 1;15(6):817–27.
- 599 17. Bos I, Vos S, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni G, et al. The
600 EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort
601 characteristics. *Alzheimers Res Ther*. 2018 Jul 6;10(1):64.
- 602 18. Reijs BLR, Ramakers IHGB, Elias-Sonnenschein L, Teunissen CE, Koel-
603 Simmelink M, Tsolaki M, et al. Relation of Odor Identification with Alzheimer’s
604 Disease Markers in Cerebrospinal Fluid and Cognition. *J Alzheimers Dis JAD*.
605 2017;60(3):1025–34.
- 606 19. Galluzzi S, Marizzoni M, Babiloni C, Albani D, Antelmi L, Bagnoli C, et al.
607 Clinical and biomarker profiling of prodromal Alzheimer’s disease in
608 workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a
609 ‘European ADNI study’. *J Intern Med*. 2016;279(6):576–91.

- 610 20. Visser PJ, Verhey FRJ, Boada M, Bullock R, De Deyn PP, Frisoni GB, et al.
611 Development of Screening Guidelines and Clinical Criteria for Predementia
612 Alzheimer's Disease. *Neuroepidemiology*. 2008 Jun;30(4):254–65.
- 613 21. van der Flier WM, Pijnenburg YAL, Prins N, Lemstra AW, Bouwman FH,
614 Teunissen CE, et al. Optimizing patient care and research: the Amsterdam
615 Dementia Cohort. *J Alzheimers Dis JAD*. 2014;41(1):313–27.
- 616 22. Somers C, Struyfs H, Goossens J, Niemantsverdriet E, Luyckx J, De Roeck N, et
617 al. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in
618 Belgium. *J Alzheimers Dis JAD*. 2016 10;54(1):383–95.
- 619 23. Fortea J, Sala-Llonch R, Bartrés-Faz D, Bosch B, Lladó A, Bargalló N, et al.
620 Increased cortical thickness and caudate volume precede atrophy in PSEN1
621 mutation carriers. *J Alzheimers Dis JAD*. 2010;22(3):909–22.
- 622 24. Adamczuk K, Schaefferbeke J, Nelissen N, Neyens V, Vandenbulcke M, Goffin
623 K, et al. Amyloid imaging in cognitively normal older adults: comparison between
624 (18)F-flutemetamol and (11)C-Pittsburgh compound B. *Eur J Nucl Med Mol*
625 *Imaging*. 2016 Jan;43(1):142–51.
- 626 25. Estanga A, Ecay-Torres M, Ibañez A, Izagirre A, Villanua J, Garcia-Sebastian M,
627 et al. Beneficial effect of bilingualism on Alzheimer's disease CSF biomarkers
628 and cognition. *Neurobiol Aging*. 2017 Feb 1;50:144–51.
- 629 26. Alcolea D, Clarimón J, Carmona-Iragui M, Illán-Gala I, Morenas-Rodríguez E,
630 Barroeta I, et al. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A
631 data set for biomarker discovery and validation in neurodegenerative disorders.
632 *Alzheimers Dement Transl Res Clin Interv*. 2019 Oct 14;5:597–609.
- 633 27. Wallin A, Nordlund A, Jonsson M, Blennow K, Zetterberg H, Öhrfelt A, et al.
634 Alzheimer's disease--subcortical vascular disease spectrum in a hospital-based
635 setting: Overview of results from the Gothenburg MCI and dementia studies. *J*
636 *Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab*. 2016
637 Jan;36(1):95–113.
- 638 28. Tautvydaitė D, Kukreja D, Antonietti J-P, Henry H, von Gunten A, Popp J.
639 Interaction between personality traits and cerebrospinal fluid biomarkers of
640 Alzheimer's disease pathology modulates cognitive performance. *Alzheimers Res*
641 *Ther*. 2017 Feb 2;9(1):6.
- 642 29. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med*. 2004
643 Sep;256(3):183–94.

- 644 30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical
645 diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group
646 under the auspices of Department of Health and Human Services Task Force on
647 Alzheimer's Disease. *Neurology*. 1984 Jul;34(7):939–44.
- 648 31. Thomas LE, O'Brien EC, Piccini JP, D'Agostino RB, Pencina MJ. Application of
649 net reclassification index to non-nested and point-based risk prediction models: a
650 review. *Eur Heart J*. 2019 Jun 14;40(23):1880–7.
- 651 32. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added
652 predictive ability of a new marker: from area under the ROC curve to
653 reclassification and beyond. *Stat Med*. 2008 Jan 30;27(2):157–72; discussion 207-
654 212.
- 655 33. Pencina MJ, Steyerberg EW, D'Agostino RB. Net reclassification index at event
656 rate: properties and relationships. *Stat Med*. 2017;36(28):4455–67.
- 657 34. Serum Levels of Acyl-Carnitines along the Continuum from Normal to
658 Alzheimer's Dementia [Internet]. [cited 2020 Sep 17]. Available from:
659 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0155694>
- 660 35. Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre-
661 and post-treatment study | Translational Psychiatry [Internet]. [cited 2020 Sep 17].
662 Available from: <https://www.nature.com/articles/s41398-018-0353-x>
- 663 36. van der Velpen V, Teav T, Gallart-Ayala H, Mehl F, Konz I, Clark C, et al.
664 Systemic and central nervous system metabolic alterations in Alzheimer's disease.
665 *Alzheimers Res Ther*. 2019 Nov 28;11(1):93.
- 666 37. von Arnim CAF, Herbolzheimer F, Nikolaus T, Peter R, Biesalski HK, Ludolph
667 AC, et al. Dietary antioxidants and dementia in a population-based case-control
668 study among older people in South Germany. *J Alzheimers Dis JAD*.
669 2012;31(4):717–24.
- 670 38. Giil LM, Midttun Ø, Refsum H, Ulvik A, Advani R, Smith AD, et al. Kynurenine
671 Pathway Metabolites in Alzheimer's Disease. *J Alzheimers Dis JAD*.
672 2017;60(2):495–504.
- 673 39. Wood PL. Lipidomics of Alzheimer's disease: current status. *Alzheimers Res*
674 *Ther*. 2012 Feb 1;4(1):5.
- 675 40. Li N, Liu W, Li W, Li S, Chen X, Bi K, et al. Plasma metabolic profiling of
676 Alzheimer's disease by liquid chromatography/mass spectrometry. *Clin Biochem*.
677 2010 Aug;43(12):992–7.

- 678 41. Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen SG, Matson W, et al.
679 Alterations in metabolic pathways and networks in Alzheimer's disease. *Transl*
680 *Psychiatry*. 2013 Apr 9;3:e244.
- 681 42. Martínez MF, Martín XE, Alcelay LG, Flores JC, Valiente JMU, Juanbeltz BI, et
682 al. The COMT Val158 Met polymorphism as an associated risk factor for
683 Alzheimer disease and mild cognitive impairment in APOE 4 carriers. *BMC*
684 *Neurosci*. 2009 Sep 30;10:125.
- 685 43. Gulyás B, Pavlova E, Kása P, Gulya K, Bakota L, Várszegi S, et al. Activated
686 MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl
687 using whole hemisphere autoradiography. *Neurochem Int*. 2011 Jan;58(1):60–8.
- 688 44. Koistinen VM, Kärkkäinen O, Borewicz K, Zarei I, Jokkala J, Micard V, et al.
689 Contribution of gut microbiota to metabolism of dietary glycine betaine in mice
690 and in vitro colonic fermentation. *Microbiome*. 2019 Jul 10;7(1):103.
- 691 45. Aswad M, Rayan M, Abu-Lafi S, Falah M, Raiyn J, Abdallah Z, et al. Nature is
692 the best source of anti-inflammatory drugs: indexing natural products for their
693 anti-inflammatory bioactivity. *Inflamm Res Off J Eur Histamine Res Soc Al*. 2018
694 Jan;67(1):67–75.
- 695 46. Sun H, Cai W, Wang X, Liu Y, Hou B, Zhu X, et al. *Vaccaria hypaphorine*
696 alleviates lipopolysaccharide-induced inflammation via inactivation of NFκB and
697 ERK pathways in Raw 264.7 cells. *BMC Complement Altern Med*. 2017 Feb
698 20;17(1):120.
- 699 47. Hartai Z, Juhász A, Rimanóczy Á, Janáky T, Donkó T, Dux L, et al. Decreased
700 serum and red blood cell kynurenic acid levels in Alzheimer's disease. *Neurochem*
701 *Int*. 2007 Jan 1;50(2):308–13.
- 702 48. Gulaj E, Pawlak K, Bien B, Pawlak D. Kynurenine and its metabolites in
703 Alzheimer's disease patients. *Adv Med Sci*. 2010 Jan 1;55(2):204–11.
- 704 49. Poeggeler B, Rassoulpour A, Wu H-Q, Guidetti P, Roberts RC, Schwarcz R.
705 Dopamine receptor activation reveals a novel, kynurenate-sensitive component of
706 striatal N-methyl-d-aspartate neurotoxicity. *Neuroscience*. 2007 Aug
707 10;148(1):188–97.
- 708 50. Raison CL, Rook GW, Miller AH, Begay TK. Chapter 26 - Role of Inflammation
709 in Psychiatric Disease. In: Zigmond MJ, Rowland LP, Coyle JT, editors.
710 *Neurobiology of Brain Disorders* [Internet]. San Diego: Academic Press; 2015
711 [cited 2021 Jan 12]. p. 396–421. Available from:
712 <http://www.sciencedirect.com/science/article/pii/B9780123982704000264>

713 **Appendix**

714 List of collaborators in European Medical Information Framework (EMIF)

715 consortium.

Organisations	Partner type	Country
Aarhus Universitetshospital	Academia	Denmark
Agenzia Regionale di Sanità	Academia	Italy
Alzheimer Europe	Patient Organisation	Luxembourg
Amgen	EFPIA	UK
Boehringer Ingelheim International GmbH	EFPIA	Germany
Cambridge Cognition Ltd	SME	UK
Concentris Research Management GmbH	SME	Germany
Custodix NV	SME	Belgium
Electrophoretics Ltd	SME	UK
Erasmus Universitair Medisch Centrum Rotterdam	Academia	The Netherlands
European Institute for Health Records	Academia	Belgium
European Molecular Biology Laboratory	Academia	Germany
F. Hoffmann-La Roche AG	EFPIA	Switzerland
Fondazione PENTA - for the Treatment and Care of Children with HIV-ONLUS	Academia	Italy
Genomedics S.R.L.	Academia	Italy
GlaxoSmithKline Research and Development Ltd	EFPIA	UK
Göteborgs Universitet	Academia	Sweden
Helsingin Yliopisto	Academia	Finland
IDIAP	Academia	Spain
Institut National de la Santé et de la Recherche Médicale	Academia	France
Itä-Suomen Yliopisto	Academia	Finland
Janssen Pharmaceutica NV	EFPIA	Belgium
Karolinska Institutet	Academia	Sweden
King's College London	Academia	UK
Leibniz Institute for Prevention, Research and Epidemiology - BIPS GmbH	Academia	Germany
Maastricht University	Academia	The Netherlands

MAAT France	SME	France
Merck	EFPIA	Germany
Novo Nordisk A/S	EFPIA	Denmark
Pedianet	SME	Italy
Pfizer	EFPIA	UK
Pharmo Cooperatie UA	SME	The Netherlands
Provincia Lombardo-Veneta - Ordine Ospedaliero di San Giovanni di Dio— Fatebenefratelli	Academia	Italy
Servier	EFPIA	France
Synapse Research Management Partners S.L.	SME	Spain
Tartu Ulikool	Academia	Estonia
Teknologian tutkimuskeskus VTT	Academia	Finland
UCB Pharma SA	EFPIA	Belgium
Universidade de Aveiro	Academia	Portugal
Universitat Pompeu Fabra	Academia	Spain
Universiteit Antwerpen	Academia	Belgium
University College London	Academia	UK
University of Copenhagen	Academia	Denmark
University of Exeter	Academia	UK
University of Glasgow	Academia	UK
University of Leicester	Academia	UK
University of Manchester	Academia	UK
University of Oxford	Academia	UK
University Pierre et Marie Curie	Academia	France
Università degli Studi di Pisa	Academia	Italy
Universität Leipzig	Academia	Germany
Universität zu Lübeck (University of Lübeck)	Academia	Germany
Universitätsklinikum Erlangen. Anstalt des Öffentlichen Rechts	Academia	Germany
Vestische Kinder - und Jugendklinik Datteln	Academia	Germany
VIB	Academia	Belgium
VU University Medical Center	Academia	The Netherlands